Hanmi Science, the holding company of Hanmi Group, announced Q2 operating profit of 59.1 billion won on 28일, marking a 70.9% increase compared to the same period last year. The growth was driven by robust performance across group subsidiaries and the company's own business competitiveness. On a consolidated basis, Q2 revenue and operating profit reached 367.9 billion won and 59.1 billion won respectively, with net profit of 43.7 billion won representing a 54.2% year-over-year increase. The results reflect balanced expansion in pharmaceutical distribution (OnlineParm) and proprietary healthcare operations, as Hanmi Science continues strengthening its portfolio beyond traditional holding company functions.
Hanmi Science Reports Q2 Operating Profit of 59.1 Billion Won
Hanmi Science disclosed on 28일 that its consolidated Q2 revenue and operating profit provisionally totaled 367.9 billion won and 59.1 billion won respectively. Revenue increased 8.7% year-over-year, while operating profit grew 70.9% compared to the same period last year. Net profit for the quarter reached 43.7 billion won, up 54.2% year-over-year.
For the first half of the year, cumulative revenue reached 721.6 billion won, a 7.6% increase from the previous year. Operating profit and net profit recorded 92.7 billion won and 86 billion won respectively during the same period.
OnlineParm Revenue Reaches 305.7 Billion Won in Q2
The company stated that the performance was driven by balanced growth across group affiliates, particularly in pharmaceutical distribution (OnlineParm) and proprietary healthcare operations. OnlineParm generated revenue of 305.7 billion won in Q2, an increase of 19.1 billion won compared to the same period last year, supported by expansion of domestic distribution business centered on ethical drugs (ETC). Profitability also improved significantly as Q2 technology export achievements from Hanmi Pharmaceutical were partially reflected in results.
Hanmi Science Expands Consumer Health Portfolio with New Brands
The company continues strengthening its own business competitiveness while fulfilling its core role as a holding company. It is expanding operations in medical devices, soymilk, health functional foods, and cosmetics under its consumer health business. Recently, Hanmi Science launched health functional food brand 'N.PL' and derma cosmetic brand 'ADESII'.
CEO Kim Jae-gyo Outlines Global Healthcare Strategy
Kim Jae-gyo, CEO of Hanmi Science, stated: "Going forward, we will maximize synergies between affiliates as an operating holding company that organically executes the group's growth strategy, and continue expanding our healthcare business portfolio to lead the leap toward becoming a global healthcare company."
Hanmi Science Stock Closes at 33,950 Won
Hanmi Science shares closed at 33,950 won on the day, down 4.37% from the previous trading session.
FAQ
What was Hanmi Science's Q2 operating profit?
Hanmi Science reported Q2 operating profit of 59.1 billion won, representing a 70.9% increase compared to the same period last year.
Why did Hanmi Science's profitability improve in Q2?
The company attributed the improvement to balanced growth across group affiliates, particularly OnlineParm's pharmaceutical distribution expansion and partial reflection of Hanmi Pharmaceutical's technology export achievements in Q2 results.
What new brands did Hanmi Science launch recently?
Hanmi Science recently launched health functional food brand 'N.PL' and derma cosmetic brand 'ADESII' as part of its consumer health business expansion.
